Key Highlights

  • Senti Biosciences (NASDAQ:SNTI) rose 28.67% to USD 0.2253 in a pre-market snapshot on Tuesday, October 27, 2026 with no dated announcement, against a pending transaction that would transfer its Gene-Circuit pipeline to a Celadon-controlled company.
  • BioCardia (NASDAQ:BCDA) rose 5.62% to USD 0.9522 after the company's release of Monday, October 19, 2026 on FDA acceptance of a De Novo pre-submission package, a procedural step and not marketing clearance.
  • Estrella Immunopharma (NASDAQ:ESLA) slipped 6.28% to USD 0.8611 after a leadership change, with cash of USD 146,670 at June 30, 2026 against a six-month net loss of USD 4.6 million.
  • Pluri Inc. (NASDAQ:PLUR) fell 8.04% to USD 1.03 with no dated announcement, while management stated that cash of USD 8.851 million covers operating obligations for less than three months.

Senti Biosciences (NASDAQ:SNTI): a pending transaction and listing notices

Senti Biosciences (NASDAQ:SNTI), a clinical-stage cell and gene therapy company, shows how a deal can frame a move without fresh news. Simple arithmetic on the snapshot implies a prior close of about USD 0.1751. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the rise, which appears consistent with thin liquidity in a share priced far below USD 1.00 and with trading around the transaction announced on Wednesday, July 15, 2026. Under it, affiliates of Celadon, the largest investor, would acquire the Gene-Circuit pipeline, including SENTI-202, while stockholders would receive a contingent value right of up to USD 60 million over seven years.

The Form 8-K of Thursday, August 27, 2026 reported Nasdaq notices of a bid price below USD 1.00 for 30 consecutive trading days, with a compliance period to Tuesday, February 23, 2027, and of a stockholders' equity deficit of USD 3,401,000 at Tuesday, June 30, 2026, against a USD 2.5 million requirement. An amendment of Tuesday, September 1, 2026 allowed a third tranche of USD 2.0 million of convertible notes. The bull reading is that SENTI-202 holds FDA RMAT designation and showed durable MRD-negative responses in a 22-patient Phase 1 leukaemia trial. The bear reading is that the right is payable only on milestones and that a reverse split and dilution from the notes are possible.

BioCardia (NASDAQ:BCDA): a regulatory step on a short runway

BioCardia (NASDAQ:BCDA), a clinical-stage company developing autologous cell therapy for cardiovascular disease and the Helix transendocardial delivery catheter, moved after a regulatory step. No company-specific announcement dated Tuesday, October 27, 2026 was identified. The company expects written FDA feedback and a meeting in the current quarter, and the move appears consistent with a delayed reaction and thin liquidity. The Helix package covers data from 15 trials with nearly 500 patients.

The release of Wednesday, August 12, 2026 reported a net loss of USD 1.6 million for the quarter ended June 30, 2026 and cash of USD 4.1 million after USD 4.9 million raised through an at-the-market offering. The financing release of Monday, June 8, 2026 said net proceeds from the sale of 3,509,604 shares at an average USD 1.279 should extend runway into the first quarter of 2027. The bull reading rests on FDA feedback on Helix and a planned Japanese PMDA Shonin (marketing approval) submission in the fourth quarter of 2026. The bear reading rests on the short runway, dilution through the offering and minimum bid price pressure with the shares near USD 1.00.

Estrella Immunopharma (NASDAQ:ESLA): early data against a thin balance sheet

Estrella Immunopharma (NASDAQ:ESLA), a clinical-stage biopharmaceutical company developing ARTEMIS T-cell therapies for cancers, announced on or about Monday, October 26, 2026 the appointment of Cynthia Pussinen as chief executive officer and chairperson. A change of chief executive on the eve of the session may have prompted repositioning, which is an inference, and the move also appears consistent with thin pre-market liquidity. A fifth clinical site opened on Wednesday, October 14, 2026.

In its quarterly report of Thursday, August 13, 2026, the company reported a net loss of USD 2.3 million for the quarter ended June 30, 2026, and simple arithmetic on the published figures shows that cash covered a small fraction of one quarter of losses. On Thursday, October 15, 2026 it reported that the first dose-expansion patient in the STARLIGHT-1 trial had received two infusions of EB103 with no treatment-related serious adverse events in the first month. The bull reading rests on a 100% complete response rate at Month 1 in the high-dose cohort of nine patients. The bear reading rests on the single-patient safety observation, dilution from required financing and Nasdaq notices of Monday, August 17, 2026 on bid price and Tuesday, September 1, 2026 on market value.

Pluri Inc. (NASDAQ:PLUR): a past-due loan and a going concern paragraph

Pluri Inc. (NASDAQ:PLUR), a biotechnology company that runs a three-dimensional cell expansion platform across cell therapy, contract manufacturing and food technology, implies a prior close of about USD 1.12, by simple arithmetic. No company-specific announcement dated on or just before Tuesday, October 27, 2026 accompanied the decline. It appears consistent with thin pre-market liquidity and with pressure on a share price now below the USD 1.50 level of the registered direct offering of Thursday, August 27, 2026, which sold 2.23 million shares with warrants.

The annual report on Form 10-K for the fiscal year ended June 30, 2026 includes a going concern paragraph from the auditor. The European Investment Bank loan of EUR 20 million carries 4% interest and fell due on June 1, 2026, with about EUR 4.1 million of accrued interest at year end. On Monday, August 17, 2026 the bank approved a proposed sale of the loan to a third party, and the company may seek to convert it into equity. The bull reading rests on the ISO 13485:2016 certification of the PluriCDMO unit in August 2026 and the Phase I PROTO study of PLX-PAD in knee osteoarthritis, begun in January 2026. The bear reading rests on dilution and on listing compliance, which requires a USD 35 million minimum market value of listed securities or an alternative standard.

Where Things Stand

The answer is that none of the four can be judged on science alone, because runway sets the pace for each. Senti Biosciences (NASDAQ:SNTI) depends on closing a transaction and on convertible note tranches. BioCardia (NASDAQ:BCDA) has a regulatory path but a short stated runway. Estrella Immunopharma (NASDAQ:ESLA) has early response data but little cash. Pluri Inc. (NASDAQ:PLUR) carries a past-due loan that any restructuring must resolve.

The next catalysts are the Federal Reserve decision of Wednesday, October 28, 2026, which follows the rate rise from 3.75% to 4.00% on Wednesday, September 16, 2026, the BioCardia FDA written feedback expected in the quarter ending Wednesday, December 31, 2026, the Estrella Nasdaq deadlines of Tuesday, February 16, 2027 and Monday, March 1, 2027 and the Senti bid price deadline of Tuesday, February 23, 2027. Pre-market prices are snapshots and can change before the open at 9:30 a.m. ET, and this is not investment advice.